BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15452398)

  • 1. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections.
    Nenoff P; Haustein UF; Hittel N
    Chemotherapy; 2004 Oct; 50(4):196-201. PubMed ID: 15452398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
    Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany.
    Alba V; Urban E; Angeles Dominguez M; Nagy E; Nord CE; Palacín C; Vila J
    Int J Antimicrob Agents; 2009 Mar; 33(3):272-5. PubMed ID: 19095414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
    Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez HT
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2875-9. PubMed ID: 16870792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes].
    Komagata Y; Komiyama K; Nomura S
    Jpn J Antibiot; 1998 Feb; 51(2):130-6. PubMed ID: 9575439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic susceptibility of conjunctival bacterial isolates from refractive surgery patients.
    Chung JL; Seo KY; Yong DE; Mah FS; Kim TI; Kim EK; Kim JK
    Ophthalmology; 2009 Jun; 116(6):1067-74. PubMed ID: 19395038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
    Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
    Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility in vitro of gram-positive aerobe and anaerobe bacteria to ofloxacin.
    Debbia E; Mannelli S; Gianrossi G; Schito GC
    Drugs Exp Clin Res; 1987; 13(4):213-7. PubMed ID: 3304918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial activity of nadifloxacin against Staphylococcus and Propionibacterium isolated from patients with dermatological infections].
    Matsuzaki K; Omika K; Hasegawa M; Sato Y; Kobayashi I
    Jpn J Antibiot; 2006 Aug; 59(4):316-20. PubMed ID: 17111596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
    Hori Y; Nakazawa T; Maeda N; Sakamoto M; Yokokura S; Kubota A; Inoue T; Nishida K; Tano Y
    J Cataract Refract Surg; 2009 Mar; 35(3):475-9. PubMed ID: 19251140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
    Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.